Michael Birrer, MD, PhD

Articles

Looking into the Future of Potential Studies Regarding IO Sequencing in Advanced EC

April 28th 2025

Panelists discuss how studies providing real-world data or large-scale randomized controlled trials (RCTs) on immuno-oncology (IO) sequencing, along with ongoing clinical trials in advanced endometrial cancer (EC), could drive changes in clinical practice by improving survival outcomes, refining patient selection, and informing treatment sequencing to enhance patient management strategies.

Second Immunotherapy Exposure: Understanding Efficacy and Safety in Endometrial and Cervical Carcinoma

April 28th 2025

Physicians discuss how recent studies have influenced their clinical practice, leading to updates in diagnostic strategies, treatment protocols, and patient communication, with a focus on evidence-based decision-making, refined therapeutic choices, and personalized care to improve patient outcomes.

Impact of Combination Therapy: Evaluating the Influence of Lenvatinib and Pembrolizumab in Relapsed Endometrial Cancer

April 21st 2025

Panelists discuss how recent studies highlight the potential of second-line immunotherapy approaches, including the pembrolizumab-lenvatinib combination and re-challenging with second-line immunotherapy, to improve outcomes in advanced endometrial cancer (EC), with an emphasis on biomarker-driven strategies, careful monitoring for toxicity, and the need for further research to optimize treatment sequencing and patient selection.

A Case Series: Activity of Pembro-Lenvatinib in dMMR EC Who Have Not Responded to Pembro-Mono

April 21st 2025

Panelists discuss how the pembrolizumab-lenvatinib combination offers promising efficacy as a second-line therapy for patients with mismatch repair deficiency (dMMR) endometrial cancer (EC) who did not respond to pembrolizumab monotherapy, with an emphasis on biomarker-driven treatment decisions, managing toxicity, and the need for further studies to refine patient selection and treatment strategies.

Real-World Use of ICI in Advanced or Recurrent Endometrial Cancer

April 14th 2025

Panelists discuss how real-world studies on immune checkpoint inhibitors (ICIs) in advanced or recurrent endometrial cancer (EC) provide valuable insights into treatment effectiveness, patient outcomes, and the management of adverse events, helping refine treatment strategies, especially for biomarker-driven therapy.

Determining Subsequent Therapies Based on Patient’s Prior Treatment History in Advanced EC

April 14th 2025

Panelists discuss how a patient's prior treatment history, including response to previous therapies, toxicity, biomarker status, and clinical trial participation, plays a critical role in determining subsequent therapy for advanced endometrial cancer (EC).

Guiding Treatment Decisions Post-IO in Advanced EC: Insights from Available Data

April 7th 2025

Panelists discuss how treatment decisions for advanced endometrial cancer (EC) patients after progressing on immune-oncology (IO) therapy are guided by clinical trial data, real-world evidence, biomarker status, initial therapy response, and patient-specific factors to personalize subsequent treatment strategies.

Key Factors Influencing IO Continuation or Discontinuation in Subsequent Lines of Treatment in Advanced EC

April 7th 2025

Panelists discuss how the decision to continue or discontinue immune-oncology (IO) therapy in subsequent lines of treatment for advanced endometrial cancer (EC) is influenced by factors such as tumor response, biomarker status, treatment tolerability, patient health, and the availability of alternative therapies.

Optimizing Management Strategies for Advanced Endometrial Cancer Progression After IO-Chemo

March 31st 2025

Panelists discuss how treating patients with advanced endometrial cancer (EC) who progress after immune-oncology (IO)-chemotherapy involves reassessing tumor biomarkers, considering alternative immunotherapies or targeted treatments, and personalizing care based on prior treatment responses and individual patient factors.

Overview of Current Treatment Landscape of Advanced Endometrial Cancer

March 31st 2025

Panelists discuss how the integration of immunotherapy, particularly immune checkpoint inhibitors (ICIs) and combination therapies, is transforming the treatment landscape of advanced endometrial cancer (EC), with a focus on biomarker-driven approaches and the ongoing role of chemotherapy.

Dr Birrer on the Potential Utility of ADCs in Platinum-Resistant Ovarian Cancer

August 22nd 2023

Michael J. Birrer, MD, PhD, discusses how the expansion of antibody-drug conjugates can address the need for more effective regimens in platinum-resistant ovarian cancer.

Dr. Birrer on Remaining Questions in Platinum-Sensitive Ovarian Cancer

March 12th 2022

Michael J. Birrer, MD, PhD, discussed remaining questions when addressing platinum-sensitive ovarian cancer.

PARP Inhibitor Therapy Options Are Transforming Landscape in Ovarian Cancer

September 4th 2020

PARP inhibitors have fundamentally changed our therapeutic algorithms in ovarian cancer, even as their use continues to evolve.

Dr. Birrer on PARP Inhibitors in Ovarian Cancer

March 29th 2018

Michael Birrer, MD, PhD, UAB Comprehensive Cancer Center in Alabama, discusses the role of PARP inhibitors in the treatment of patients with ovarian cancer.

Dr. Birrer on Checkpoint Inhibitors for Endometrial Cancer

June 20th 2017

Michael Birrer, MD, PhD, UAB Comprehensive Cancer Center in Alabama, discusses checkpoint inhibitors for patients with endometrial cancer.

Dr. Birrer on Prevalence of Cervical Cancer in the United States

January 9th 2017

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses the prevalence of cervical cancer in the United States.

Dr. Birrer on Challenges With Patient Demographics in Cervical Cancer

January 5th 2017

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses the challenges associated with the patient demographics of cervical cancer.

Dr. Birrer on Patient Preferences for Cervical Cancer Treatment

December 29th 2016

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses patient preferences for cervical cancer treatment, as well as the demographics of this population.

Dr. Birrer on FDA Approval of Rucaparib in Ovarian Cancer

December 19th 2016

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses the FDA approval of rucaparib for as a treatment for patients with BRCA-positive advanced ovarian cancer who have received at least 2 prior lines of chemotherapy.

Dr. Birrer on the Need for Novel Treatment Options in Cervical Cancer

December 13th 2016

Michael Birrer, MD, PhD, director of Medical Gynecologic Oncology at Massachusetts General Hospital, discusses some of the novel treatment options that could be explored in the future treatment of patients with cervical cancer.

x